A global consensus definition of acute-on-chronic liver failure: A major step forward for hepatology

Share

The five major international liver societies — the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), Asian Pacific Association for the Study of the Liver (APASL), Latin American Association for the Study of the Liver (ALEH), and Society on Liver Disease in Africa (SOLDA) — have published a joint consensus definition of acute-on-chronic liver failure (ACLF).1 The consensus was also presented Nov. 7 at The Liver Meeting 2026 in Denver. This follows a major international effort to bring together different perspectives and establish a common approach to the definition, diagnosis, grading, and management of ACLF.

Brian Kim, MD, FACG, FAASLD, associate editor, GI & Hepatology News

ACLF is a severe, life-threatening syndrome characterized by acute deterioration in liver function in patients with underlying chronic liver disease, accompanied by extrahepatic organ dysfunction or failure and associated with high short-term mortality. The term "acute-on-chronic liver failure" was coined by Ohnishi and colleagues in 1995.2 Since then, ACLF has increasingly been recognized as a distinct clinical entity, with short-term mortality that may exceed even that seen in acute liver failure.1 Over the past three decades, several studies and working groups convened by different liver societies have proposed definitions and diagnostic criteria for ACLF. Although there has been general agreement that ACLF develops in patients with preexisting chronic liver disease following an acute insult, such as infection, resulting in hepatic and extrahepatic organ dysfunction, there have been important differences in how these components are defined. In particular, the thresholds used to identify liver failure and extrahepatic organ dysfunction have varied among groups. This has made it difficult to compare studies, establish consistent approaches to clinical management, and design clinical trials with comparable patient populations.

To address these differences, experts from the five major liver societies came together to develop a common definition and recommendations for the diagnosis and management of ACLF. Central to the proposed definition is the requirement for liver failure, defined as an international normalized ratio (INR) of at least 1.5 and serum bilirubin of at least 5 mg/dL. Following an acute precipitating event, ACLF can develop in patients with compensated advanced chronic liver disease or cirrhosis, as well as in those with previously decompensated cirrhosis. In both groups, liver failure is accompanied by one or more extrahepatic organ dysfunctions or failures. Both hepatic and extrahepatic events may contribute to the development of ACLF. Disease severity is graded according to the number and nature of extrahepatic organ dysfunctions and failures involved (Table 1).

The consensus also goes beyond defining ACLF to provide recommendations for its management, taking into account the precipitating event, the type of organ dysfunction, and overall disease severity. This is particularly important given the complexity of managing these patients, who often require urgent and coordinated care across several specialties.

A common definition has clear potential benefits. It should allow more consistent recognition and diagnosis of ACLF across centers and geographic regions, improve prognostic assessment, and help guide decisions about intensive care, organ support, and liver transplantation.

One of the areas where this consensus could have the greatest impact is clinical research. Differences in ACLF definitions have made it difficult to compare studies, particularly when patients recruited in different parts of the world may not have had the same clinical characteristics. Agreed diagnostic criteria should make it easier to conduct international multicenter studies and clinical trials, with more consistent patient selection, severity grading, and outcome assessment. This will be important as we look to evaluate new treatments and identify which patients are most likely to benefit from them. The proposed definition will, of course, need prospective validation, but having a common starting point is an important step toward making progress in this area.

It is genuinely exciting to see this work come to fruition. Bringing together five major global liver societies to agree on a common definition of ACLF is no small achievement, and the benefits are likely to extend well beyond the immediate clinical implications. Just as important as the consensus itself is that these societies worked together to achieve it. Each brings a different perspective on and experience with ACLF, reflecting the differences in patient populations and clinical practice across the world. Reaching agreement across these groups demonstrates the value of putting those differences aside and working toward a common goal. We hope this will encourage similar collaborations in other areas of medicine. Progress on many complex clinical problems would benefit from greater international cooperation and a willingness to reach consensus. This initiative is a good example of what can be achieved when we work together, and we hope it will ultimately lead not only to better research and understanding of ACLF but also to better care for our patients worldwide.

Dr. Kim reported having no conflicts of interest.

References

1. AASLD, EASL, APASL, ALEH, SOLDA. Acute-on-chronic liver failure: a global multisociety consensus on definitions. Hepatology. Published online 2026. doi:10.1097/HEP.0000000000001891

2. Ohnishi H, Sugihara J, Moriwaki H, Muto Y. Acute-on-chronic liver failure. Ryoikibetsu Shokogun Shirizu. 1995;7:217-219.

Table 1: Grades of ACLF

Grade

Definition

1

Liver failure (INR ≥1.5 and bilirubin ≥5 mg/dL) and one EHOD (circulatory/respiratory only if in a monitored/semi-monitored setting)

2

Liver failure (INR ≥1.5 and bilirubin ≥5 mg/dL) and one EHOF

3

Liver failure (INR ≥1.5 and bilirubin ≥5 mg/dL) and ≥2 EHOFs

ACLF, acute-on-chronic liver failure; EHOD, extrahepatic organ dysfunction; EHOF, extrahepatic organ failure; INR, international normalized ratio. Adapted from AASLD, et al. 2026.1

Dr. Kim is an associate professor of clinical medicine at the University of Southern California Keck School of Medicine and is a transplant hepatologist specializing in the treatment of patients with acute and chronic liver disease, cirrhosis, and hepatocellular carcinoma. Dr. Kim’s clinical research interests include liver transplantation, living donor liver transplantation, cardiac diseases in liver patients, and complications of portal hypertension. He has authored numerous chapters and articles in peer-reviewed journals on various topics in liver disease, liver transplantation, and education. He currently serves as the Program Director for the ACGME-accredited Gastroenterology and Hepatology Fellowship at USC and serves as the chair of the USC Keck School of Medicine GI/Liver Course.